With all the enormous resources that are invested in medicine, it is sometimes a mystery why there is so much sickness still in evidence. Our life span, though higher than at any time in history, has now leveled off and has not significantly increased in the last two generations. There is a one-third increase in long-term illness in the last 20 years and a 44% increase in cancer incidence, which are not related to demographic issues. In some modern countries, the level of morbidity (defined as days off work because of sickness) has increased by two thirds in this time. Despite $1 trillion spent on cancer research in 20 years, the "War On Cancer" has recently been pronounced a complete failure by the u. s. President's Cancer Panel. Evidently we still have a long way to go. The goal of "Health for All by the Year 2000" as the World Health Organization has put it, is another forgotten dream. As ever, the answer will be found in breaking out of the old philosophical patterns and discovering the new, as yet unacceptable concepts. The problems of medicine today require a Kuhnian breakthrough into new paradigms, and new ways of thinking. And these new ways will not be mere variations of the old, but radical departures. This book, and the conference upon which it was based, is part of a search for these new pathways.

With all the enormous resources that are invested in medicine, it is sometimes a mystery why there is so much sickness still in evidence. Our life span, though higher than at any time in history, has now leveled off and has not significantly increased in the last two generations. There is a one-third increase in long-term illness in the last 20 years and a 44% increase in cancer incidence, which are not related to demographic issues. In some modern countries, the level of morbidity (defined as days off work because of sickness) has increased by two thirds in this time. Despite $1 trillion spent on cancer research in 20 years, the "War On Cancer" has recently been pronounced a complete failure by the u. s. President's Cancer Panel. Evidently we still have a long way to go. The goal of "Health for All by the Year 2000" as the World Health Organization has put it, is another forgotten dream. As ever, the answer will be found in breaking out of the old philosophical patterns and discovering the new, as yet unacceptable concepts. The problems of medicine today require a Kuhnian breakthrough into new paradigms, and new ways of thinking. And these new ways will not be mere variations of the old, but radical departures. This book, and the conference upon which it was based, is part of a search for these new pathways.

With all the enormous resources that are invested in medicine, it is sometimes a mystery why there is so much sickness still in evidence. Our life span, though higher than at any time in history, has now leveled off and has not significantly increased in the last two generations. There is a one-third increase in long-term illness in the last 20 years and a 44% increase in cancer incidence, which are not related to demographic issues. In some modern countries, the level of morbidity (defined as days off work because of sickness) has increased by two thirds in this time. Despite $1 trillion spent on cancer research in 20 years, the "War On Cancer" has recently been pronounced a complete failure by the u. s. President's Cancer Panel. Evidently we still have a long way to go. The goal of "Health for All by the Year 2000" as the World Health Organization has put it, is another forgotten dream. As ever, the answer will be found in breaking out of the old philosophical patterns and discovering the new, as yet unacceptable concepts. The problems of medicine today require a Kuhnian breakthrough into new paradigms, and new ways of thinking. And these new ways will not be mere variations of the old, but radical departures. This book, and the conference upon which it was based, is part of a search for these new pathways.

Naltrexone is an opiate antagonist drug developed in the 1970s and approved by the FDA in 1984 for opiate and drug abuse treatment. When used at much lower doses in an off-label protocol referred to as low dose naltrexone (LDN), the drug has been shown to halt disease progression in Crohn's disease and certain cancers, to reduce symptoms in multiple sclerosis and autism, and to improve numerous autoimmune and neurodegenerative conditions, including Parkinson's disease and amyotrophic lateral sclerosis (ALS). Grounded in clinical and scientific research, this book describes the history of naltrexone, its potential therapeutic uses, its effects on the immune system, its pharmacological properties, and how the drug is administered. It also lists fillers and compounding pharmacies, doctors who prescribe LDN, and patient resources, and includes interviews with LDN patients and researchers.

Recent Advances in Medicine and Health Sciences: Concepts, Researches and Practice

This New York Times–bestselling book upends conventional thinking about autism and suggests a broader model for acceptance, understanding, and full participation in society for people who think differently. What is autism? A lifelong disability, or a naturally occurring form of cognitive difference akin to certain forms of genius? In truth, it is all of these things and more—and the future of our society depends on our understanding it. Wired reporter Steve Silberman unearths the secret history of autism, long suppressed by the same clinicians who became famous for discovering it, and finds surprising answers to the crucial question of why the number of diagnoses has soared in recent years. Going back to the earliest days of autism research, Silberman offers a gripping narrative of Leo Kanner and Hans Asperger, the research pioneers who defined the scope of autism in profoundly different ways; he then goes on to explore the game-changing concept of neurodiversity. NeuroTribes considers the idea that neurological differences such as autism, dyslexia, and ADHD are not errors of nature or products of the toxic modern world, but the result of natural variations in the human genome. This groundbreaking book will reshape our understanding of the history, meaning, function, and implications of neurodiversity in our world.